ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]

read more

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]

read more
Showing 11 to 12 of 12 results
  TOP